Drug–drug interactions of telaprevir and boceprevir in HCV‐monoinfected and HIV/HCV‐coinfected patients can modify the adherence

Abstract

More than half of the patients were at risk of presenting DDIs, leading to changes in the baseline medication in one-third of the patients. Drug interactions are frequent in patients with lower adherence.

Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine

“…Treatment regimens for both conditions often involve the coadministration of multiple drugs, which may have overlapping metabolic enzyme, transporter, and/or elimination pathways. In clinical practice, use of medications with DDI potential is commonplace among patients with HCV/HIV coinfection who are initiating treatment with a direct-acting antiviral agent (DAA), a drug class that has emerged as a mainstay of HCV treatment (4). For certain DAAs, caution or avoidance of use in combination with several ARV regimens, such as tenofovir disoproxil fumarate (tenofovir DF)-based treatments, is advised owing to alterations in drug exposures (5).…”

Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir‐based regimens: results from ERCHIVES

“…The pill burden and drug–drug interactions with the first generation of DAAs (boceprevir and telaprevir) posed challenges to clinicians and patients. At least one potential drug–drug interaction was found in more than half of the patients on these drugs, and those with the drug–drug interaction were less likely to be adherent to therapy and have a lower SVR rate . Conversely, treatment for HCV itself is associated with increased adherence to highly active antiretroviral therapy in patients co‐infected with the human immunodeficiency virus .…”